AAAAAA

   
Results: 1-20 |
Results: 20
The long-term safety and efficacy of pramipexole in advanced Parkinson's disease
Authors: Weiner, WJ Factor, SA Jankovic, J Hauser, RA Tetrud, JW Waters, CH Shulman, LM Glassman, PM Beck, B Paume, D Doyle, C
Citation: Wj. Weiner et al., The long-term safety and efficacy of pramipexole in advanced Parkinson's disease, PARKINS R D, 7(2), 2001, pp. 115-120
Focal myopathy as a cause of anterocollis in Parkinsonism
Authors: Lava, NS Factor, SA
Citation: Ns. Lava et Sa. Factor, Focal myopathy as a cause of anterocollis in Parkinsonism, MOVEMENT D, 16(4), 2001, pp. 754-756
Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial
Authors: Factor, SA Friedman, JH Lannon, MC Oakes, D Bourgeois, K
Citation: Sa. Factor et al., Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial, MOVEMENT D, 16(1), 2001, pp. 135-139
Long-term comparative experience with tolcapone and entacapone in advancedParkinson's disease
Authors: Factor, SA Molho, ES Feustel, PJ Brown, DL Evans, SM
Citation: Sa. Factor et al., Long-term comparative experience with tolcapone and entacapone in advancedParkinson's disease, CLIN NEUROP, 24(5), 2001, pp. 295-299
A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events
Authors: Dewey, RB Hutton, JT LeWitt, PA Factor, SA
Citation: Rb. Dewey et al., A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events, ARCH NEUROL, 58(9), 2001, pp. 1385-1392
Atypical antipsychotics: Clozapine-related cardiac complications - Reply
Authors: Friedman, JH Factor, SA
Citation: Jh. Friedman et Sa. Factor, Atypical antipsychotics: Clozapine-related cardiac complications - Reply, MOVEMENT D, 15(6), 2000, pp. 1300-1300
Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease
Authors: Friedman, JH Factor, SA
Citation: Jh. Friedman et Sa. Factor, Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease, MOVEMENT D, 15(2), 2000, pp. 201-211
The initial treatment of Parkinson's disease
Authors: Factor, SA
Citation: Sa. Factor, The initial treatment of Parkinson's disease, MOVEMENT D, 15(2), 2000, pp. 360-361
Subcutaneous apomorphine injections as a treatment for intractable pain inParkinson's disease
Authors: Factor, SA Brown, DL Molho, ES
Citation: Sa. Factor et al., Subcutaneous apomorphine injections as a treatment for intractable pain inParkinson's disease, MOVEMENT D, 15(1), 2000, pp. 167-169
Emergency department presentations of patients with Parkinson's disease
Authors: Factor, SA Molho, ES
Citation: Sa. Factor et Es. Molho, Emergency department presentations of patients with Parkinson's disease, AM J EMER M, 18(2), 2000, pp. 209-215
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia
Authors: Hauser, RA Friedlander, J Zesiewicz, TA Adler, CH Seeberger, LC O'Brien, CF Molho, ES Factor, SA
Citation: Ra. Hauser et al., A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia, CLIN NEUROP, 23(2), 2000, pp. 75-81
Ropinirole as compared with levodopa in Parkinson's disease
Authors: Weiner, WJ Factor, SA
Citation: Wj. Weiner et Sa. Factor, Ropinirole as compared with levodopa in Parkinson's disease, N ENG J MED, 343(12), 2000, pp. 885-885
An extended 5 '-tau susceptibility haplotype in progressive supranuclear palsy
Authors: Higgins, JJ Golbe, LI De Biase, A Jankovic, J Factor, SA Adler, RL
Citation: Jj. Higgins et al., An extended 5 '-tau susceptibility haplotype in progressive supranuclear palsy, NEUROLOGY, 55(9), 2000, pp. 1364-1367
Worsening of motor features of Parkinsonism with olanzapine
Authors: Molho, ES Factor, SA
Citation: Es. Molho et Sa. Factor, Worsening of motor features of Parkinsonism with olanzapine, MOVEMENT D, 14(6), 1999, pp. 1014-1016
Possible tardive dystonia resulting from clozapine therapy
Authors: Molho, ES Factor, SA
Citation: Es. Molho et Sa. Factor, Possible tardive dystonia resulting from clozapine therapy, MOVEMENT D, 14(5), 1999, pp. 873-874
Transient benefit of amantadine in Parkinson's disease: The facts about the myth
Authors: Factor, SA Molho, ES
Citation: Sa. Factor et Es. Molho, Transient benefit of amantadine in Parkinson's disease: The facts about the myth, MOVEMENT D, 14(3), 1999, pp. 515-517
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia
Authors: Brin, MF Lew, MF Adler, CH Comella, CL Factor, SA Jankovic, J O'Brien, C Murray, JJ Wallace, JD Willmer-Hulme, A Koller, M
Citation: Mf. Brin et al., Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia, NEUROLOGY, 53(7), 1999, pp. 1431-1438
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia
Authors: Brashear, A Lew, MF Dykstra, DD Comella, CL Factor, SA Rodnitzky, RL Trosch, R Singer, C Brin, MF Murray, JJ Wallace, JD Willmer-Hulme, A Koller, M
Citation: A. Brashear et al., Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia, NEUROLOGY, 53(7), 1999, pp. 1439-1446
Acute delirium after withdrawal of amantadine in Parkinson's disease - Reply
Authors: Factor, SA Molho, ES Brown, DL
Citation: Sa. Factor et al., Acute delirium after withdrawal of amantadine in Parkinson's disease - Reply, NEUROLOGY, 52(8), 1999, pp. 1720-1721
Dopamine agonists
Authors: Factor, SA
Citation: Sa. Factor, Dopamine agonists, MED CLIN NA, 83(2), 1999, pp. 415
Risultati: 1-20 |